Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.
| Revenue (TTM) | $13.60B |
| Gross Profit (TTM) | $4.26B |
| EBITDA | $1.08B |
| Operating Margin | 5.76% |
| Return on Equity | 8.85% |
| Return on Assets | 4.39% |
| Revenue/Share (TTM) | $116.77 |
| Book Value | $28.21 |
| Price-to-Book | 3.17 |
| Price-to-Sales (TTM) | 0.73 |
| EV/Revenue | 1.004 |
| EV/EBITDA | 13.53 |
| Quarterly Earnings Growth (YoY) | 17.10% |
| Quarterly Revenue Growth (YoY) | 6.70% |
| Shares Outstanding | $111.45M |
| Float | $91.42M |
| % Insiders | 0.84% |
| % Institutions | 111.73% |
Volatility is currently contracting
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call Transcript
Henry Schein NASDAQ: HSIC reported higher second-quarter sales, operating margins and earnings, citing accelerating internal sales growth, market-share gains in dental merchandise and early benefits from its value-creation program. The company also raised its full-year sales and adjusted earnings guidance.
Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HSIC and any ticker you trade — then tracks every position and per-strategy win rate.
